These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 38324313)
1. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial. Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313 [TBL] [Abstract][Full Text] [Related]
2. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial. Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061 [TBL] [Abstract][Full Text] [Related]
3. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H; Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509 [TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial. Wallström J; Geterud K; Kohestani K; Maier SE; Pihl CG; Socratous A; Stranne J; Arnsrud-Godtman R; Månsson M; Hellström M; Hugosson J Eur Urol Oncol; 2022 Feb; 5(1):54-60. PubMed ID: 34580053 [TBL] [Abstract][Full Text] [Related]
5. Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population. Fredsøe J; Sandahl M; Vedsted P; Jensen JB; Ulhøi BP; Borre M; Sørensen KD; Pedersen BG; Eur Urol Oncol; 2023 Oct; 6(5):484-492. PubMed ID: 37537016 [TBL] [Abstract][Full Text] [Related]
6. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial. Auvinen A; Tammela TLJ; Mirtti T; Lilja H; Tolonen T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Natunen K; Nevalainen J; Raitanen J; Ronkainen J; van der Kwast T; Riikonen J; Pétas A; Matikainen M; Taari K; Kilpeläinen T; Rannikko AS; JAMA; 2024 May; 331(17):1452-1459. PubMed ID: 38581254 [TBL] [Abstract][Full Text] [Related]
7. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Boschheidgen M; Albers P; Schlemmer HP; Hellms S; Bonekamp D; Sauter A; Hadaschik B; Krilaviciute A; Radtke JP; Seibold P; Lakes J; Arsov C; Gschwend JE; Herkommer K; Makowski M; Kuczyk MA; Wacker F; Harke N; Debus J; Körber SA; Benner A; Kristiansen G; Giesel FL; Antoch G; Kaaks R; Becker N; Schimmöller L Eur Urol; 2024 Feb; 85(2):105-111. PubMed ID: 37863727 [TBL] [Abstract][Full Text] [Related]
8. Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING). Wetterauer C; Matthias M; Pueschel H; Deckart A; Bubendorf L; Mortezavi A; Arbelaez E; Jean Winkel D; Heye T; Boll DT; Merkle E; Hayoz S; Seifert HH; Rentsch CA Eur Urol Focus; 2024 Mar; 10(2):332-338. PubMed ID: 38402105 [TBL] [Abstract][Full Text] [Related]
9. Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study. Rannikko A; Leht M; Mirtti T; Kenttämies A; Tolonen T; Rinta-Kiikka I; Kilpeläinen TP; Natunen K; Lilja H; Lehtimäki T; Raitanen J; Kujala P; Ronkainen J; Matikainen M; Petas A; Taari K; Tammela T; Auvinen A BJU Int; 2022 Aug; 130(2):193-199. PubMed ID: 34958531 [TBL] [Abstract][Full Text] [Related]
10. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer. Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899 [TBL] [Abstract][Full Text] [Related]
11. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study. Eldred-Evans D; Burak P; Connor MJ; Day E; Evans M; Fiorentino F; Gammon M; Hosking-Jervis F; Klimowska-Nassar N; McGuire W; Padhani AR; Prevost AT; Price D; Sokhi H; Tam H; Winkler M; Ahmed HU JAMA Oncol; 2021 Mar; 7(3):395-402. PubMed ID: 33570542 [TBL] [Abstract][Full Text] [Related]
12. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate. Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068 [TBL] [Abstract][Full Text] [Related]
13. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients. Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594 [TBL] [Abstract][Full Text] [Related]
14. An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study. Eldred-Evans D; Tam H; Sokhi H; Padhani AR; Connor M; Price D; Gammon M; Klimowska-Nassar N; Burak P; Day E; Winkler M; Fiorentino F; Ahmed HU Eur Urol Oncol; 2023 Jun; 6(3):295-302. PubMed ID: 37080821 [TBL] [Abstract][Full Text] [Related]
15. Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men. Bratt O; Godtman RA; Jiborn T; Wallström J; Akre O; Carlsson S; Nordström T; Thimansson E; Alterbeck M; Zackrisson S; Hugosson J; Bjartell A; Lantz A Eur Urol; 2024 Mar; 85(3):207-214. PubMed ID: 38042646 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial. Klotz L; Chin J; Black PC; Finelli A; Anidjar M; Bladou F; Mercado A; Levental M; Ghai S; Chang SD; Milot L; Patel C; Kassam Z; Moore C; Kasivisvanathan V; Loblaw A; Kebabdjian M; Earle CC; Pond GR; Haider MA JAMA Oncol; 2021 Apr; 7(4):534-542. PubMed ID: 33538782 [TBL] [Abstract][Full Text] [Related]
17. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. Eklund M; Jäderling F; Discacciati A; Bergman M; Annerstedt M; Aly M; Glaessgen A; Carlsson S; Grönberg H; Nordström T; N Engl J Med; 2021 Sep; 385(10):908-920. PubMed ID: 34237810 [TBL] [Abstract][Full Text] [Related]
18. A pilot study of an organised population-based testing programme for prostate cancer. Alterbeck M; Thimansson E; Bengtsson J; Baubeta E; Zackrisson S; Bolejko A; Sandeman K; Carlsson S; Jiborn T; Bjartell A BJU Int; 2024 Jan; 133(1):87-95. PubMed ID: 37523331 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men. Russo F; Mazzetti S; Regge D; Ambrosini I; Giannini V; Manfredi M; De Luca S; Bollito E; Porpiglia F Eur Urol Oncol; 2021 Dec; 4(6):855-862. PubMed ID: 33893066 [TBL] [Abstract][Full Text] [Related]
20. Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis. Fazekas T; Shim SR; Basile G; Baboudjian M; Kói T; Przydacz M; Abufaraj M; Ploussard G; Kasivisvanathan V; Rivas JG; Gandaglia G; Szarvas T; Schoots IG; van den Bergh RCN; Leapman MS; Nyirády P; Shariat SF; Rajwa P JAMA Oncol; 2024 Jun; 10(6):745-754. PubMed ID: 38576242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]